Bryan, Texas – Sano Chemicals today announced the start of a Phase 1, first-in-human clinical trial, of Occidiofungin, a new chemical entity under development as a treatment to cure recurrent vulvovaginal candidiasis (RVVC). There are up to 9 million women in the US that have RVVC, which is characterized as having three or more yeast infections per year. RVVC is classified as an unmet medical need and Sano Chemicals has been granted Qualified Infectious Disease Product and Fast Track designations from the Food and Drug Administration. Phase 1 clinical trials are underway to establish Occidiofungin as a cure for RVVC. Sano Chemicals is developing additional products using Occidiofungin as a treatment for oral, dermal, and invasive infections that are in preclinical development.
“The development of a drug product using Occidiofungin is supported by peer reviewed research and safety data. Occidiofungin is a first-in-class agent being developed for potential cure and worldwide use”, says James Leif Smith, Co-CEO of Sano Chemicals.
Occidiofungin is fungicidal and is being developed as a cure for infection and not as a suppressive therapy. The existing therapies on the market are suppressive and lead to increase in resistance to currently available antifungal drugs.
“RVVC is an unmet medical need that affects millions of women worldwide. This means that there is still no effective cure for a vast majority of women and the market opportunity for a drug product to treat RVVC is massive”, says Janice Miles, Co-CEO of Sano Chemicals.
Recruitment in the trial is underway and the trial enrollment is expected to be completed by March 2024.
ABOUT SANO CHEMICALS
Sano Chemicals is a clinical-stage company developing new chemical entities for providing an effective treatment for those with unmet medical needs. Novel agents are in development that intend to lessen the burden of multidrug resistant infectious diseases and cancer. Sano Chemicals is also developing new first-in-class antibacterial agents that have a dual mechanism of action against bacteria that have developed resistance to currently available antibiotics. A drug product containing the antifungal Occidiofungin is being developed as a cure for recurrent vulvovaginal candidiasis (RVVC). Occidiofungin is designated as a Qualified Infectious Disease Product (QIDP) and has been Fast Tracked by the FDA.
For more information, please visit www.sanochemicals.com.
James Smith, Co-CEO: firstname.lastname@example.org
Janice Miles, Co-CEO: email@example.com